Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,586 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo:0.9% sodium chloride Clear all
Completed Not applicable Interventional Results available

NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy

NCT02107300
View directory record Official record
Conditions
Xerostomia
Interventions
NeutraSal, Placebo Comparator
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 84 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence

NCT02296099
View directory record Official record
Conditions
Urinary Incontinence, Stress
Interventions
liposomal bupivacaine, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Results available

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

NCT00822926
View directory record Official record
Conditions
Pain
Interventions
Botulinum Toxin Type A, Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

NCT04839965
View directory record Official record
Conditions
COVID-19
Interventions
Ampion, Saline
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347016
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

NCT03218384
View directory record Official record
Conditions
Iron-deficiency
Interventions
Ferric Carboxymaltose, Placebo, 31P MRS/MRI
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

NCT06297499
View directory record Official record
Conditions
Pruritus Caused by Drug
Interventions
Ondansetron 8mg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

NCT04808414
View directory record Official record
Conditions
Bacterial Infections
Interventions
QPX9003 for IV Infusion, Placebo for IV infusion
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Nitrous Oxide for PTSD

NCT04378426
View directory record Official record
Conditions
PTSD
Interventions
Nitrous Oxide, Midazolam, Nitrogen, Oxygen, Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

NCT07625293
View directory record Official record
Conditions
Crohn Disease (CD)
Interventions
DB-3Q, Placebo
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504
View directory record Official record
Conditions
Norovirus Prevention
Interventions
Norovirus Bivalent VLP Vaccine, Placebo (Saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

NCT02966314
View directory record Official record
Conditions
Idiopathic Angioedema
Interventions
Omalizumab, Placebos
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Tranexamic Acid in Reduction Mammoplasty

NCT04947514
View directory record Official record
Conditions
Hematoma Postoperative, Venous Thromboembolism
Interventions
Tranexamic acid, Placebo (topical saline)
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

NCT01737814
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Disease
Interventions
Saline, MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cells for Erectile Dysfunction Post RALP

NCT07048314
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR, Placebo in clinic
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 4 Interventional

Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty

NCT02299271
View directory record Official record
Conditions
Osteoarthritis of the Hip
Interventions
Ropivacaine, Saline
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Not listed Phase 2 Interventional

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

NCT04060316
View directory record Official record
Conditions
Sinusitis Chronic
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Safety of SonoVue on Pulmonary Hemodynamics

NCT01306292
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
SonoVue, Placebo
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of SLN Block for Chronic Cough

NCT04421092
View directory record Official record
Conditions
Cough, Superior Laryngeal Nerve Block, Neurogenic Cough
Interventions
Superior laryngeal nerve block, Injection of placebo (saline), Injection of steroid-lidocaine mixture
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 16, 2026, 4:40 PM EDT